Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Study hypothesis: Non-invasive positive pressure ventilation delivered by helmet will reduce 28-day all-cause mortality in patients with suspected or confirmed severe COVID-19 pneumonia and acute hypoxemic respiratory failure
Description: all cause mortality
Measure: 28-day all-cause mortality Time: 28 days from randomizationDescription: endotracheal intubation
Measure: Requirement for endotracheal intubation within 28 days Time: 28 days from randomizationDescription: ICU death
Measure: ICU mortality Time: 180 days from randomizationDescription: hospital death
Measure: Hospital mortality Time: 180 days from randomizationDescription: days not in ICU
Measure: ICU free days at day 28 Time: 28 days from randomizationDescription: days without ventilator support
Measure: Ventilator free days at day 28 Time: 28 days from randomizationDescription: days without renal replacement therapy received
Measure: Renal replacement therapy free days at day 28 Time: 28 days from randomizationDescription: days without vasopressor support
Measure: Vasopressor free days at day 28 Time: 28 days from randomizationDescription: presence of pressure ulcers
Measure: Skin pressure ulcers Time: 28 days from randomizationDescription: tolerance to intervention
Measure: Tolerance of helmet (>1-hour use) Time: 28 days from randomizationDescription: vital status
Measure: 180-day mortality Time: 180 days from randomizationDescription: The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.
Measure: 180-day 5-level EQ-5D version Time: 180 days from randomizationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports